Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT02926690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer
Study identification
- NCT ID
- NCT02926690
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- OncoTherapy Science, Inc.
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- OTS167PO Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2017
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
- Last update posted
- Feb 24, 2026
2017 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Norwalk Hospital | Norwalk | Connecticut | 06856 | Completed |
| Emory University, Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| Kapi'olani Medical Center for Women & Children | Honolulu | Hawaii | 96826 | Recruiting |
| Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | Recruiting |
| Weill Cornell Medicine | NewYork-Presbyterian | New York | New York | 10065 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 11065 | Completed |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Completed |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02926690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02926690 live on ClinicalTrials.gov.